Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/t-cell-avidity-and-tumor-immunity-problems-and-solutions-qMTuNSa04F
References (78)
-
S Zhong, K Malecek, LA Johnson (2013)
T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapyProc Natl Acad Sci U S A, 110
-
A. Kalergis, Nicole Boucheron, M. Doucey, E. Palmieri, E. Goyarts, Z. Végh, I. Luescher, S. Nathenson (2001)
Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complexNature Immunology, 2
-
P. Robbins, Yong Li, M. El-Gamil, Yangbing Zhao, J. Wargo, Zhili Zheng, Hui Xu, R. Morgan, S. Feldman, L. Johnson, A. Bennett, S. Dunn, T. Mahon, B. Jakobsen, S. Rosenberg (2008)
Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell FunctionsThe Journal of Immunology, 180
-
Rachel McMahan, Jennifer McWilliams, Kimberly Jordan, S. Dow, Darcy Wilson, J. Slansky (2006)
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.The Journal of clinical investigation, 116 9
-
M. Irving, V. Zoete, Michael Hebeisen, D. Schmid, P. Baumgartner, P. Guillaume, P. Romero, D. Speiser, I. Luescher, N. Rufer, O. Michielin (2012)
Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8+ T Cell Responsiveness*The Journal of Biological Chemistry, 287
-
L. Johnson, R. Morgan, M. Dudley, L. Cassard, J. Yang, M. Hughes, U. Kammula, R. Royal, R. Sherry, J. Wunderlich, C. Lee, N. Restifo, S. Schwarz, Alexandria Cogdill, R. Bishop, Hung Kim, C. Brewer, Susan Rudy, C. Vanwaes, Jeremy Davis, A. Mathur, R. Ripley, Debbie-Ann Nathan, C. Laurencot, S. Rosenberg (2009)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.Blood, 114 3
-
George Liu, P. Fairchild, Richard Smith, J. Prowle, D. Kioussis, D. Wraith (1995)
Low avidity recognition of self-antigen by T cells permits escape from central tolerance.Immunity, 3 4
-
E. Corse, Rachel Gottschalk, M. Krogsgaard, J. Allison (2010)
Attenuated T Cell Responses to a High-Potency Ligand In VivoPLoS Biology, 8
-
J. Kochenderfer, W. Wilson, J. Janik, M. Dudley, M. Stetler-Stevenson, S. Feldman, I. Maric, M. Raffeld, Debbie-Ann Nathan, B. Lanier, R. Morgan, S. Rosenberg (2010)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.Blood, 116 20
-
M. Alexander-Miller, G. Leggatt, J. Berzofsky (1996)
Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.Proceedings of the National Academy of Sciences of the United States of America, 93 9
-
B. Till, M. Jensen, Jinjuan Wang, E. Chen, B. Wood, H. Greisman, Xiaojun Qian, Scott James, A. Raubitschek, S. Forman, A. Gopal, J. Pagel, C. Lindgren, P. Greenberg, S. Riddell, O. Press (2008)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.Blood, 112 6
-
P. Holler, D. Kranz (2003)
Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation.Immunity, 18 2
-
E. Shusta, P. Holler, Michele Kieke, D. Kranz, K. Wittrup (2000)
Directed evolution of a stable scaffold for T-cell receptor engineeringNature Biotechnology, 18
-
R. Teague, Blythe Sather, J. Sacks, Maria Huang, M. Dossett, J. Morimoto, Xiao-hua Tan, S. Sutton, M. Cooke, Claes Öhlén, P. Greenberg (2006)
Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumorsNature Medicine, 12
-
Ingo Bartholomäus, N. Kawakami, F. Odoardi, Christian Schläger, D. Miljković, J. Ellwart, W. Klinkert, C. Flügel-Koch, T. Issekutz, H. Wekerle, A. Flügel (2009)
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesionsNature, 462
-
J. Snyder, M. Alexander-Miller, Jay Berzofskyl, I. Belyakov (2003)
Molecular mechanisms and biological significance of CTL avidity.Current HIV research, 1 3
-
O. Borbulevych, Sujatha Santhanagopolan, M. Hossain, B. Baker (2011)
TCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct MechanismsThe Journal of Immunology, 187
-
C. Janicki, S. Jenkinson, N. Williams, D. Morgan (2008)
Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.Cancer research, 68 8
-
V. Weiss, Timothy Lee, E. Jaffee, T. Armstrong (2012)
Targeting the right regulatory T-cell population for tumor immunotherapyOncoimmunology, 1
-
P. Robbins, R. Morgan, S. Feldman, J. Yang, R. Sherry, M. Dudley, J. Wunderlich, Azam Nahvi, L. Helman, C. Mackall, U. Kammula, M. Hughes, N. Restifo, M. Raffeld, C. Lee, Catherine Levy, Yong Li, M. El-Gamil, S. Schwarz, C. Laurencot, S. Rosenberg (2011)
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 7
-
L. Pace, Andy Tempez, Catharina Arnold-Schrauf, F. Lemaître, P. Bousso, L. Fetler, T. Sparwasser, S. Amigorena (2012)
Regulatory T Cells Increase the Avidity of Primary CD8+ T Cell Responses and Promote MemoryScience, 338
-
N. Restifo, M. Dudley, S. Rosenberg (2012)
Adoptive immunotherapy for cancer: harnessing the T cell responseNature Reviews Immunology, 12
-
M. Parkhurst, J. Yang, R. Langan, M. Dudley, Debbie-Ann Nathan, S. Feldman, Jeremy Davis, R. Morgan, M. Merino, R. Sherry, M. Hughes, U. Kammula, G. Phan, Ramona Lim, S. Wank, N. Restifo, P. Robbins, C. Laurencot, S. Rosenberg (2011)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis.Molecular therapy : the journal of the American Society of Gene Therapy, 19 3
-
C. King, S. Koehli, B. Hausmann, M. Schmaler, D. Zehn, E. Palmer (2012)
T cell affinity regulates asymmetric division, effector cell differentiation, and tissue pathology.Immunity, 37 4
-
N. Chinnasamy, J. Wargo, Zhiya Yu, Mahadev Rao, T. Frankel, J. Riley, Jenny Hong, M. Parkhurst, S. Feldman, D. Schrump, N. Restifo, P. Robbins, S. Rosenberg, R. Morgan (2011)
A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of CancerThe Journal of Immunology, 186
-
Angel Varela-Rohena, P. Molloy, S. Dunn, Yi Li, M. Suhoski, R. Carroll, A. Milicic, T. Mahon, Deborah Sutton, Bruno Laugel, R. Moysey, Brian Cameron, A. Vuidepot, M. Purbhoo, D. Cole, R. Phillips, C. June, B. Jakobsen, A. Sewell, J. Riley (2008)
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptorNature Medicine, 14
-
R. Mallone, S. Kochik, H. Reijonen, B. Carson, S. Ziegler, W. Kwok, G. Nepom (2005)
Functional avidity directs T-cell fate in autoreactive CD4+ T cells.Blood, 106 8
-
Victoria Brentville, R. Metheringham, B. Gunn, L. Durrant (2012)
High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional ImpairmentPLoS ONE, 7
-
K. Shafer-Weaver, M. Anderson, Katherine Stagliano, A. Malyguine, N. Greenberg, A. Hurwitz (2009)
Cutting Edge: Tumor-Specific CD8+ T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells1The Journal of Immunology, 183
-
R. Morgan, N. Chinnasamy, D. Abate-Daga, A. Gros, P. Robbins, Zhili Zheng, M. Dudley, S. Feldman, J. Yang, R. Sherry, G. Phan, M. Hughes, U. Kammula, A. Miller, C. Hessman, Ashley Stewart, N. Restifo, M. Quezado, M. Alimchandani, A. Rosenberg, A. Nath, Tongguang Wang, B. Bielekova, Simone Wuest, N. Akula, F. McMahon, S. Wilde, Barbara Mosetter, D. Schendel, C. Laurencot, S. Rosenberg (2013)
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene TherapyJournal of Immunotherapy, 36
-
Yangbing Zhao, A. Bennett, Zhili Zheng, Qiong Wang, P. Robbins, Lawrence Yu, Yi Li, P. Molloy, S. Dunn, B. Jakobsen, S. Rosenberg, R. Morgan (2007)
High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines1The Journal of Immunology, 179
-
M. Ahmadzadeh, L. Johnson, B. Heemskerk, J. Wunderlich, M. Dudley, D. White, S. Rosenberg (2009)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.Blood, 114 8
-
M. Krogsgaard, Shi Zhong, K. Malecek, L. Johnson, Zhiya Yu, E. Miera, F. Darvishian, Katelyn McGary-Shipper, Kevin Huang, Joshua Boyer, E. Corse, Y. Shao, S. Rosenberg, N. Restifo, I. Osman (2013)
T cell receptor affinity and avidity defines antitumor response and autoimmunity in T cell immunotherapyJournal for Immunotherapy of Cancer, 1
-
P. Hackett, D. Largaespada, L. Cooper (2010)
A transposon and transposase system for human application.Molecular therapy : the journal of the American Society of Gene Therapy, 18 4
-
A. O’Garra, P. Vieira (2004)
Regulatory T cells and mechanisms of immune system controlNature Medicine, 10
-
T. Bullock, D. Mullins, T. Colella, V. Engelhard (2001)
Manipulation of Avidity to Improve Effectiveness of Adoptively Transferred CD8+ T Cells for Melanoma Immunotherapy in Human MHC Class I-Transgenic Mice1The Journal of Immunology, 167
-
Yi Li, R. Moysey, P. Molloy, A. Vuidepot, T. Mahon, Emma Baston, S. Dunn, N. Liddy, J. Jacob, B. Jakobsen, J. Boulter (2005)
Directed evolution of human T-cell receptors with picomolar affinities by phage displayNature Biotechnology, 23
-
D. Donermeyer, K. Weber, D. Kranz, P. Allen (2006)
The Study of High-Affinity TCRs Reveals Duality in T Cell Recognition of Antigen: Specificity and Degeneracy1The Journal of Immunology, 177
-
S. Ugel, E. Scarselli, M. Iezzi, C. Mennuni, T. Pannellini, F. Calvaruso, B. Cipriani, R. Palma, L. Ricci-Vitiani, E. Peranzoni, P. Musiani, P. Zanovello, V. Bronte (2010)
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes.Blood, 115 7
-
Z. Eshhar, N. Bach, C. Fitzer-Attas, Gidi Grosse, J. Lustgarten, T. Waks, D. Schindler (2004)
The T-body approach: potential for cancer immunotherapySpringer Seminars in Immunopathology, 18
-
V. Marin, E. Cribioli, B. Philip, Sarah Tettamanti, I. Pizzitola, A. Biondi, E. Biagi, M. Pule (2012)
Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.Human gene therapy methods, 23 6
-
P. Yu, C. Haymaker, R. Divekar, J. Ellis, J. Hardaway, R. Jain, D. Tartar, Christine Hoeman, Jason Cascio, Austin Ostermeier, H. Zaghouani (2008)
Fetal Exposure to High-Avidity TCR Ligand Enhances Expansion of Peripheral T Regulatory Cells1The Journal of Immunology, 181
-
M. Chapon, C. Randriamampita, E. Maubec, C. Badoual, Stéphane Fouquet, Shu-Fang Wang, E. Marinho, D. Farhi, M. Garcette, S. Jacobelli, A. Rouquette, A. Carlotti, A. Girod, A. Prévost-Blondel, A. Trautmann, M. Avril, N. Bercovici (2011)
Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.The Journal of investigative dermatology, 131 6
-
D. Zehn, Sarah Lee, M. Bevan (2009)
Complete but curtailed T cell response to very low affinity antigenNature, 458
-
Anik Côté, Peisheng Zhang, Jeremy O'Sullivan, V. Jacobs, Carli Clemis, S. Sakaguchi, J. Guevara-Patiño, M. Turk (2011)
Stimulation of the Glucocorticoid-Induced TNF Receptor Family-Related Receptor on CD8 T Cells Induces Protective and High-Avidity T Cell Responses to Tumor-Specific AntigensThe Journal of Immunology, 186
-
M. Dudley, J. Wunderlich, P. Robbins, J. Yang, P. Hwu, D. Schwartzentruber, S. Topalian, R. Sherry, N. Restifo, Amy Hubicki, M. Robinson, M. Raffeld, P. Duray, C. Seipp, Linda Rogers-Freezer, K. Morton, S. Mavroukakis, D. White, S. Rosenberg (2002)
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 298
-
A. Banerjee, Ajithkumar Vasanthakumar, G. Grigoriadis (2013)
Modulating T regulatory cells in cancer: how close are we?Immunology and Cell Biology, 91
-
E. McCormack, K. Adams, N. Hassan, Akhil Kotian, N. Lissin, Malkit Sami, Maja Mujić, Tereza Osdal, B. Gjertsen, D. Baker, A. Powlesland, M. Aleksić, A. Vuidepot, O. Morteau, Deborah Sutton, C. June, M. Kalos, R. Ashfield, B. Jakobsen (2012)
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumorsCancer Immunology, Immunotherapy, 62
-
V. Weiss, Timothy Lee, Hong-ping Song, Theodore Kouo, Chelsea Black, G. Sgouros, E. Jaffee, T. Armstrong (2012)
Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T CellsPLoS ONE, 7
-
J. Weber (2009)
Ipilimumab: controversies in its development, utility and autoimmune adverse eventsCancer Immunology, Immunotherapy, 58
-
N. Liddy, G. Bossi, K. Adams, A. Lissina, T. Mahon, N. Hassan, J. Gavarret, F. Bianchi, N. Pumphrey, K. Ladell, E. Gostick, A. Sewell, N. Lissin, Naomi Harwood, P. Molloy, Yi Li, Brian Cameron, Malkit Sami, Emma Baston, P. Todorov, S. Paston, Rebecca Dennis, Jane Harper, S. Dunn, R. Ashfield, Andrew Johnson, Y. McGrath, G. Plesa, C. June, M. Kalos, D. Price, A. Vuidepot, Daniel Williams, Deborah Sutton, B. Jakobsen (2012)
Monoclonal TCR-redirected tumor cell killingNature Medicine, 18
-
V. Dutoit, V. Rubio‐Godoy, P. Dietrich, Anne-Lise Quiqueres, V. Schnuriger, D. Rimoldi, D. Liénard, D. Speiser, P. Guillaume, P. Batard, J. Cerottini, Pedro Romero, D. Valmori (2001)
Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.Cancer research, 61 15
-
(2007)
CD8+ T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate -
C. Baum, A. Schambach, J. Bohne, Melanie Galla (2006)
Retrovirus vectors: toward the plentivirus?Molecular therapy : the journal of the American Society of Gene Therapy, 13 6
-
Hyun-Il Cho, E. Celis (2009)
Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects.Cancer research, 69 23
-
O. Caballero, Yao-Tseng Chen (2009)
Cancer/testis (CT) antigens: Potential targets for immunotherapyCancer Science, 100
-
M. Pule, B. Savoldo, G. Myers, C. Rossig, H. Russell, G. Dotti, M. Huls, E. Liu, A. Gee, Z. Mei, E. Yvon, H. Weiss, Hao Liu, C. Rooney, H. Heslop, M. Brenner (2008)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 14
-
R. Morgan, M. Dudley, J. Wunderlich, M. Hughes, J. Yang, R. Sherry, R. Royal, S. Topalian, U. Kammula, N. Restifo, Zhili Zheng, Azam Nahvi, Christiaan Vries, Linda Rogers-Freezer, S. Mavroukakis, S. Rosenberg (2006)
Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 314
-
M. Schreurs, A. Eggert, A. Boer, J. Vissers, T. Hall, R. Offringa, C. Figdor, G. Adema (2000)
Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.Cancer research, 60 24
-
Yiyuan Yin, Yili Li, R. Mariuzza (2012)
Structural basis for self‐recognition by autoimmune T‐cell receptorsImmunological Reviews, 250
-
Misty Jenkins, A. Tsun, J. Stinchcombe, G. Griffiths (2009)
The Strength of T Cell Receptor Signal Controls the Polarization of Cytotoxic Machinery to the Immunological SynapseImmunity, 31
-
V. Singh, Qingyong Ji, L. Feigenbaum, R. Leighty, A. Hurwitz (2009)
Melanoma Progression Despite Infiltration by In Vivo-primed TRP-2–specific T CellsJournal of Immunotherapy, 32
-
Ziqiang Zhu, V. Singh, S. Watkins, V. Bronte, J. Shoe, L. Feigenbaum, A. Hurwitz (2013)
High-avidity T cells are preferentially tolerized in the tumor microenvironment.Cancer research, 73 2
-
John Chang, V. Palanivel, I. Kinjyo, F. Schambach, A. Intlekofer, A. Banerjee, Sarah Longworth, Kristine Vinup, Paulus Mrass, J. Oliaro, N. Killeen, J. Orange, S. Russell, W. Weninger, S. Reiner (2007)
Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune ResponsesScience, 315
-
G. Phan, Peter Attia, S. Steinberg, D. White, S. Rosenberg (2001)
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 15
-
S. Thomas, H. Stauss, E. Morris (2010)
Molecular immunology lessons from therapeutic T‐cell receptor gene transferImmunology, 129
-
H. Moreau, F. Lemaître, E. Terriac, G. Azar, M. Piel, A. Lennon-Duménil, P. Bousso (2012)
Dynamic in situ cytometry uncovers T cell receptor signaling during immunological synapses and kinapses in vivo.Immunity, 37 2
-
M. Coccoris, T. Straetemans, C. Govers, C. Lamers, S. Sleijfer, R. Debets (2010)
T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studiesExpert Opinion on Biological Therapy, 10
-
L. Johnson, B. Heemskerk, D. Powell, C. Cohen, R. Morgan, M. Dudley, P. Robbins, S. Rosenberg (2006)
Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1The Journal of Immunology, 177
-
H. Zeh, D. Perry-Lalley, M. Dudley, S. Rosenberg, J. Yang (1999)
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.Journal of immunology, 162 2
-
S. Jameson, F. Carbone, M. Bevan (1993)
Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cellsThe Journal of Experimental Medicine, 177
-
S. Pedersen, M. Sørensen, S. Buus, J. Christensen, A. Thomsen (2013)
Comparison of Vaccine-Induced Effector CD8 T Cell Responses Directed against Self- and Non–Self-Tumor Antigens: Implications for Cancer ImmunotherapyThe Journal of Immunology, 191
-
D. Schmid, M. Irving, V. Posevitz, Michael Hebeisen, Anita Posevitz-Fejfár, J. Sarria, R. Gomez-Eerland, M. Thome, T. Schumacher, P. Romero, D. Speiser, V. Zoete, O. Michielin, N. Rufer (2010)
Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell FunctionThe Journal of Immunology, 184
-
P. Antony, C. Piccirillo, A. Akpinarli, S. Finkelstein, P. Speiss, D. Surman, D. Palmer, C. Chan, C. Klebanoff, W. Overwijk, S. Rosenberg, N. Restifo (2005)
CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory CellsThe Journal of Immunology, 174
-
H. Kessels, M. Boom, H. Spits, E. Hooijberg, T. Schumacher (2000)
Changing T cell specificity by retroviral T cell receptor display.Proceedings of the National Academy of Sciences of the United States of America, 97 26
-
M. Sadelain (2009)
T-cell engineering for cancer immunotherapy.Cancer journal, 15 6
-
A. Elsas, A. Hurwitz, J. Allison (1999)
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune DepigmentationThe Journal of Experimental Medicine, 190
-
C. Yee, P. Savage, P. Lee, Mark Davis, P. Greenberg (1999)
Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.Journal of immunology, 162 4
- Publisher
- Springer Journals
- Copyright
- Copyright © 2013 by Springer Science+Business Media Dordrecht (outside the USA)
- Subject
- Biomedicine; Cancer Research; Oncology; Immunology; Cell Biology; Biochemistry, general; Biomedicine general
- ISSN
- 1875-2292
- eISSN
- 1875-2284
- DOI
- 10.1007/s12307-013-0143-1
- pmid
- 24357332
- Publisher site
- See Article on Publisher Site
Abstract
A potent T cell response is an important component of durable anti-tumor immunity. The quality of the T cell response can, in-part, be measured by the avidity of the T cell for its tumor antigen-expressing target. While convention suggests that raising the avidity of the responding T cells may make for a more potent anti-tumor immune response, the threshold for effective tumor immunity remains unclear, as do some of the adverse effects of an inappropriately high avidity response. In this review, we discuss the relationship between T cell avidity and anti-tumor immunity, considering both experimental model systems as well as human clinical trials.
Journal
Cancer Microenvironment – Springer Journals
Published: Dec 20, 2013